Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial

达帕格列嗪 依普利酮 医学 泌尿科 肾脏疾病 内科学 肌酐 蛋白尿 肾功能 交叉研究 盐皮质激素受体 药理学 内分泌学 醛固酮 安慰剂 糖尿病 2型糖尿病 病理 替代医学
作者
Michele Provenzano,María Jesús Puchades,Carlo Garofalo,Niels Jongs,Luis D’Marco,Michele Andreucci,Luca De Nicola,José Luis Górriz,Hiddo J.L. Heerspink
出处
期刊:Journal of The American Society of Nephrology 卷期号:33 (8): 1569-1580 被引量:83
标识
DOI:10.1681/asn.2022020207
摘要

Significance Statement In this randomized crossover clinical trial in patients with CKD with and without type 2 diabetes, we assessed the albuminuria-lowering effect of the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin and mineralocorticoid receptor antagonist (MRA) eplerenone individually and in combination. We demonstrated that the albuminuria-lowering effects of dapagliflozin and eplerenone alone are additive when they are used in combination, resulting in a clinically relevant albuminuria reduction of 53% after 4 weeks of dapagliflozin-eplerenone treatment. The incidence of hyperkalemia was significantly less with combination treatment compared with eplerenone alone. These data support future clinical trials to confirm long-term efficacy and safety of combined SGLT2 inhibitor and MRA treatment. Background Sodium glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists (MRAs) reduce the urinary albumin-to-creatinine ratio (UACR) and confer kidney and cardiovascular protection in patients with CKD. We assessed efficacy and safety of the SGLT2 inhibitor dapagliflozin and MRA eplerenone alone and in combination in patients with CKD. Methods We conducted a randomized open-label crossover trial in patients with urinary albumin excretion ≥100 mg/24 hr, eGFR 30–90 ml/min per 1.73 m 2 , who had been receiving maximum tolerated stable doses of an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB). Patients were assigned to 4-week treatment periods with dapagliflozin 10 mg/day, eplerenone 50 mg/day, or their combination in random order, separated by 4-week washout periods. Primary outcome was the correlation in UACR changes between treatments. Secondary outcome was the percent change in 24-hour UACR from baseline. Results Of 57 patients screened, 46 were randomly assigned (mean eGFR, 58.1 ml/min per 1.73 m 2 ; median UACR, 401 mg/g) to the three groups. Mean percentage change from baseline in UACR after 4 weeks of treatment with dapagliflozin, eplerenone, and dapagliflozin-eplerenone was –19.6% (95% confidence interval [CI], –34.3 to –1.5), –33.7% (95% CI, –46.1 to –18.5), and –53% (95% CI, –61.7 to –42.4; P <0.001 versus dapagliflozin; P =0.01 versus eplerenone). UACR change during dapagliflozin or eplerenone treatment did not correlate with UACR change during dapagliflozin-eplerenone ( r =–0.13; P =0.47; r =–0.08; P =0.66, respectively). Hyperkalemia was more frequently reported with eplerenone ( n =8; 17.4%) compared with dapagliflozin ( n =0; 0%) or dapagliflozin-eplerenone ( n =2; 4.3%; P between-groups =0.003). Conclusions Albuminuria changes in response to dapagliflozin and eplerenone did not correlate, supporting systematic rotation of these therapies to optimize treatment. Combining dapagliflozin with eplerenone resulted in a robust additive UACR-lowering effect. A larger trial in this population is required to confirm long-term efficacy and safety of combined SGLT2 inhibitor and MRA treatment. Clinical Trial registry name and registration number: European Union Clinical Trials Register, EU 2017–004641–25.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
tetrakis完成签到,获得积分10
刚刚
今夕何夕完成签到,获得积分10
1秒前
沧海一兰完成签到,获得积分10
2秒前
幸福大碗完成签到,获得积分10
3秒前
小庄完成签到 ,获得积分10
3秒前
jtksbf完成签到 ,获得积分10
3秒前
谨慎寻冬完成签到,获得积分10
3秒前
4秒前
TUTU应助李高宗采纳,获得20
5秒前
Owen应助啦啦啦采纳,获得10
5秒前
SYC完成签到,获得积分10
6秒前
Tim完成签到 ,获得积分10
6秒前
陈陈完成签到,获得积分10
9秒前
tesla发布了新的文献求助20
9秒前
big ben完成签到 ,获得积分10
9秒前
典雅的太阳完成签到,获得积分10
9秒前
杠赛来完成签到,获得积分10
10秒前
DJ完成签到,获得积分10
10秒前
scienceljk完成签到,获得积分10
12秒前
ning完成签到,获得积分10
12秒前
pl完成签到 ,获得积分10
12秒前
万能图书馆应助fdpb采纳,获得10
12秒前
啊呜完成签到,获得积分10
13秒前
不甜完成签到 ,获得积分10
13秒前
Simmy完成签到,获得积分10
13秒前
11完成签到,获得积分10
14秒前
本草石之寒温完成签到 ,获得积分10
15秒前
拼搏的代玉完成签到,获得积分10
15秒前
HAn完成签到,获得积分10
15秒前
16秒前
七七完成签到,获得积分10
16秒前
yufanhui应助杨青月采纳,获得10
16秒前
祖问筠完成签到,获得积分10
16秒前
Lucas应助sapphire_yy采纳,获得10
18秒前
蒋海完成签到 ,获得积分10
18秒前
badada完成签到,获得积分10
18秒前
19秒前
Yinw完成签到 ,获得积分10
19秒前
重要无极完成签到,获得积分0
19秒前
20秒前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Дружба 友好报 (1957-1958) 1000
The Data Economy: Tools and Applications 1000
Mantiden - Faszinierende Lauerjäger – Buch gebraucht kaufen 700
PraxisRatgeber Mantiden., faszinierende Lauerjäger. – Buch gebraucht kaufe 700
A Dissection Guide & Atlas to the Rabbit 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3099895
求助须知:如何正确求助?哪些是违规求助? 2751334
关于积分的说明 7613172
捐赠科研通 2403314
什么是DOI,文献DOI怎么找? 1275235
科研通“疑难数据库(出版商)”最低求助积分说明 616318
版权声明 599053